METOPIMAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H27N3O3S2
Molecular Weight	445.598
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(=O)(=O)C1=CC=C2SC3=C(C=CC=C3)N(CCCN4CCC(CC4)C(N)=O)C2=C1

InChI

InChIKey=BQDBKDMTIJBJLA-UHFFFAOYSA-N

InChI=1S/C22H27N3O3S2/c1-30(27,28)17-7-8-21-19(15-17)25(18-5-2-3-6-20(18)29-21)12-4-11-24-13-9-16(10-14-24)22(23)26/h2-3,5-8,15-16H,4,9-14H2,1H3,(H2,23,26)

HIDE SMILES / InChI

Description
Sources: https://link.springer.com/article/10.2165/00024669-200605020-00006 | https://www.ncbi.nlm.nih.gov/pubmed/6130555

Metopimazine, a phenothiazine derivative, is a dopamine D2 receptor antagonist. It exerts its antiemetic effects via the chemoreceptor trigger zone. Metopimazine showed potent alpha-adrenergic blocking activity, showed histamine H1 antagonism, and induced palpebral ptosis. Metopimazine can occasionally be associated with orthostatic hypotension, which probably relates to its affinity for the α1-adrenoceptor. Therapeutic doses of metopimazine are likely to produce sedation and side-effects related to autonomic blockade. Metopimazine (Vogalene®) is indicated for the prevention and treatment of nausea and vomiting.

Approval Year

PubMed

Title	Date	PubMed
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy.	2003 Sep 17	14521717
Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.	2005 Nov	16307696
A randomized, double-blind trial assessing the efficacy and safety of sublingual metopimazine and ondansetron in the prophylaxis of chemotherapy-induced delayed emesis.	2006 Feb	16428941
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.	2007 Mar 31	21221195
Investigational use of metomidate hydrochloride as a shipping additive for two ornamental fishes.	2009 Sep	20043397
Fragmentation pathways of metopimazine and its metabolite using ESI-MS(n), HR-MS and H/D exchange.	2010 Oct	20690157
Development and validation of stability indicating HPLC and HPTLC methods for determination of sulpiride and mebeverine hydrochloride in combination.	2010 Sep	20538381

Sample Use Guides

In Vivo Use Guide

Adults:Take 1 orodispersible tablet at the onset of symptoms. If symptoms persist or return, treatment may be continued to a maximum of 4 tablets (= 30 mg of metopimazine) per day. Children over 6 years:Take 1 orodispersible tablet at the onset of symptoms. If symptoms persist or return, treatment may be continued to a maximum of 2 tablets (= 15 mg of metopimazine) per day.

Route of Administration: Oral

Name

Type

Language

METOPIMAZINE

Official Name

English

METOPIMAZINE [MI]

Common Name

English

Metopimazine [WHO-DD]

Common Name

English

1-[3-[2-(Methylsulfonyl)phenothiazin-10-yl]propyl]isonipecotamide

Systematic Name

English

4-PIPERIDINECARBOXAMIDE, 1-(3-(2-(METHYLSULFONYL)-10H-PHENOTHIAZIN-10-YL)PROPYL)-

Systematic Name

English

EXP 999

Code

English

metopimazine [INN]

Common Name

English

METOPIMAZINE [MART.]

Common Name

English

METOPIMAZINE [USAN]

Common Name

English

EXP-999

Code

English

Classification Tree Code System Code

WHO-VATC

QA04AD05